Nasdaq-listed Wellgistics Health is placing XRP at the center of both its balance sheet strategy and operating payments stack. In a registration statement filed with the U.S. Securities and Exchange Commission, the company said it is pursuing a public offering of common stock and related warrants, while outlining a broader digital asset strategy built around XRP for treasury management and payment flows.
The filing says the offering would be conducted on a “reasonable best efforts” basis through a placement agent and would carry no minimum closing threshold. The securities package includes common stock, prefunded warrants, and placement agent warrants. More notably, Wellgistics said it intends to adopt XRP as an ongoing treasury reserve asset, subject to market conditions and the company’s expected cash needs.
XRP as a Reserve Asset
According to the preliminary prospectus, Wellgistics believes XRP could improve financial flexibility and transaction efficiency across its healthcare distribution and technology network. The company said it may acquire XRP using cash flows above working capital requirements. It also left the door open to raising capital through equity, debt, or other financing transactions and using some of those proceeds to buy XRP. The filing indicates that once XRP becomes its primary treasury reserve asset, the company expects to continue accumulating it over time.
Payments Integration Plans
Beyond treasury holdings, Wellgistics said it plans to integrate blockchain-based payment solutions into its platform so it can accept payments in XRP. Management said this would broaden payment options for customers while allowing the company to hold and transact in the asset directly. In the filing, XRP is framed not only as a real-time settlement tool but also as a potential hedge against inflationary pressures.
Regulatory Uncertainty Still Matters
At the same time, the company acknowledged that regulatory risk remains a major variable. While a May 2025 settlement resolved the SEC’s litigation against Ripple Labs over certain XRP sales, Wellgistics noted that XRP’s definitive regulatory classification is still not fully settled. That means the company’s XRP-focused strategy, despite its ambitious scope, will likely depend on future market conditions, financing execution, and the direction of U.S. regulatory policy.